Tourmaline Bio, Inc. financial data

Symbol
TRML on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
27 West 24 Th Street, Suite 702, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Talaris Therapeutics, Inc. (to 10/18/2023)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.94K % +129%
Debt-to-equity 2.4 % -92.7%
Return On Equity -19 % +28.2%
Return On Assets -18.5 % -263%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.6M shares -40%
Common Stock, Shares, Outstanding 25.6M shares -39.7%
Entity Public Float 89.9M USD -35.4%
Common Stock, Value, Issued 3K USD -25%
Weighted Average Number of Shares Outstanding, Basic 25.7M shares +2498%
Weighted Average Number of Shares Outstanding, Diluted 25.7M shares +2498%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 38.9M USD +262%
General and Administrative Expense 22.1M USD +225%
Operating Income (Loss) -61M USD -804%
Net Income (Loss) Attributable to Parent -49.3M USD -606%
Earnings Per Share, Basic 14.5 USD/shares +95.8%
Earnings Per Share, Diluted 14.5 USD/shares +95.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 70.1M USD -19.5%
Marketable Securities, Current 79.9M USD -54.4%
Cash, Cash Equivalents, and Short-term Investments 230M USD
Other Assets, Current 1.49M USD +92.3%
Assets, Current 298M USD +90.9%
Property, Plant and Equipment, Net 65K USD -71.2%
Operating Lease, Right-of-Use Asset 290K USD -64.9%
Intangible Assets, Net (Excluding Goodwill) 0 USD
Goodwill 0 USD
Other Assets, Noncurrent 1.2M USD +985%
Assets 345M USD +117%
Accounts Payable, Current 2.39M USD -18.6%
Accrued Liabilities, Current 3.75M USD -40.9%
Liabilities, Current 6.36M USD -37.2%
Operating Lease, Liability, Noncurrent 109K USD -74.4%
Other Liabilities, Noncurrent 39K USD +255%
Liabilities 6.51M USD -39.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -452K USD -111%
Retained Earnings (Accumulated Deficit) -92.8M USD +54%
Stockholders' Equity Attributable to Parent 338M USD
Liabilities and Equity 345M USD +117%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD -294%
Net Cash Provided by (Used in) Financing Activities 161M USD
Net Cash Provided by (Used in) Investing Activities -189M USD
Common Stock, Shares Authorized 140M shares 0%
Common Stock, Shares, Issued 25.6M shares -39.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.4M USD -1012%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 70.4M USD -19.4%
Deferred Tax Assets, Valuation Allowance 34M USD +784%
Deferred Tax Assets, Gross 35.9M USD +808%
Operating Lease, Liability 415K USD -85.6%
Depreciation 10K USD +66.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -49.7M USD -741%
Lessee, Operating Lease, Liability, to be Paid 486K USD -84.8%
Property, Plant and Equipment, Gross 123K USD +41.4%
Operating Lease, Liability, Current 224K USD -62.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 227K USD -75.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 221K USD -79.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.16 pure +138%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 71K USD -76.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 38K USD -95%
Deferred Tax Assets, Operating Loss Carryforwards 5.48M USD +2001%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 437K USD
Operating Lease, Payments 200K USD -77.8%
Additional Paid in Capital 432M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 436K USD +46.8%
Deferred Tax Assets, Net of Valuation Allowance 1.85M USD +1691%
Share-based Payment Arrangement, Expense 8.14M USD +330%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares